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1. Introduction 
Colorectal cancer is the fourth most common cancer in men and the third most common one 
in women worldwide (Parkin, 2004; Parkin et al., 2005), accounting for approximately 
436,000 incident cases and 212,000 deaths in 2008 (Quirke et al., 2011). This cancer has an 
important economic impact, estimating that in the initial, continuing and last year of life 
phases of care a total of more than $7 billion were spent (Yabroff et al., 2008). Randomized 
trials have shown that systematic screening of a target population of suitable age can reduce 
colorectal cancer by detecting asymptomatic lesions (Center et al., 2009).  
Although there are differences in the etiologies and epidemiology of colon and rectal cancer 
(Giovannucci & Wu, 2006), the majority of the studies chose to examine colon and rectum 
cancers combined. However, a better understanding of these diseases nowadays, shows that 
these differences have an important impact in their approaches. First of all, the location of 
the tumours may determines different locations of metastisation. Unlike colon cancers, 
distal rectal tumours may first metastasize to the lungs because the inferior rectal veins 
drain into the inferior vena cava rather than into the portal venous system. The histological 
type can also vary. The vast majority of colorectal tumours are adenocarcinomas but 11-17% 
are mucinous carcinomas. This type, which has a penchant for the rectum and sigmoid 
colon, tends to be present at a more advanced stage (Consorti et al., 2000). The carcinoid 
tumours have a different clinical presentation too, depending on whether they appear in the 
rectum or in the colon (Marshall & Badnarchuk 1993; Spread et al., 1994). The rectum 
carcinoids develop at a young age, most of which are less than 2 cm and tend to be indolent. 
In contrast, colonic carcinoid tumours can be clinically aggressive and often metastise. 
With a more accurate review, we can see that many habits could influence the development 
of rectal cancers and not colon cancers. Some studies support the view that family history, as 
well as the level of physical activity, is a stronger contributor to colon cancer relative to 
rectal cancer (Wei et al., 2004). The Women’s Health Initiative (a large cohort study) (Paskett 
et al., 2007) also found a significant link between active cigarette smoking (not passive 
exposure to cigarette smoke) and rectal but not colon cancer. 
These differences are important in terms of monitoring and have implications in treatment 
options, as well. Compared to colon cancers, the sensitivity of CT scan for detection of 
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malignant lymph nodes is higher for rectal cancers. Any perirectal adenopathy is presumed 
to be malignant since benign adenopathies are not typically seen in this area (Thoemi, 1997). 
In a general form, rectal cancer shows predominance in male sex with a global worldwide 
incidence in this group of 13/100,000 by year. The incidence rates vary markedly worldwide 
with rates per 100,000 among males in the period of 1998-2002 reported to range from 2, 0 in 
India (New Delhi) to 31, 6 in Canada (Northwest Territories). In Europe the lowest rates in 
male were registered in Iceland (7, 6) followed by Italy- Salerno Providence (8, 1) and the 
highest in Czech Republic (27) followed by Slovak Republic (24, 4), (Curado et al., 2007). 
A top ten ranking of age-standardized (world) incidence rates in Europe by sex and country 
can be seen in Table 1. 
 
MEN WOMEN 
Rank Country Rate Rank Country Rate 
1 Czech Republic 27,0 1 Czech Republic 12,1 
2 Slovak Republic 24,4 2 Croatia 10,9 
3 Croatia 20,9 3 Slovak Republic 10,5 
4 Slovenia 20,5 4 Slovenia 10,1 
5 Ireland 18,3 4 Norway 10,1 
6 The Netherlands 17,6 5 The Netherlands 10,0 
7 Germany 17,4 6 Denmark 9,8 
8 Belgium 17,2 7 Russia 9,7 
9 Denmark 16,6 8 Germany 9,1 
10 Russia 16,6 9 Belgium 9,0 
   10 Serbia 8,5 
Data Source: Curado et al., 2007 
Table 1. Top Ten Ranking (descending form) of age- standardized (world) incidence rates by 
sex and country.  
Factors that may have contributed to the worldwide variation in incidence patterns include 
differences in the prevalence of risk factors and screening practices. Established and 
suspected  modifiable risk factors for rectal cancer, including obesity, physical inactivity, 
smoking, heavy alcohol consumption, a diet high in red or processed meats and inadequate 
consumption of fruits and vegetables (Giovanucci, 2002; Schottemfeld & Fraumeni, 2006;  
Botteri et al., 2008), which are also associated with economic development or westernization 
(Popkin, 1994). For example, in Czech Republic, nearly 60% of men are cigarette smokers 
(Shafey et al., 2003) and more than 25% of adults are obese (Berghofer et al., 2008). In Japan, 
the increased intake of milk, meat, eggs and fat/oil over the past several decades has 
contributed to the increase in obesity in this country (Kuriki & Tajima, 2006; Matsushita et 
al., 2008).  
In Portugal, particularly in the county of Vila Nova de Gaia (North of country) in the period 
of 2004- 2006 there were, on average 35 new cases per 100,000 inhabitants which, as showed, 
constitutes one of the highest rates in the world (Abreu et al., 2010). 
In this chapter, the authors propose to examine the evolution of rectal cancer epidemiology 
based on the data of an active population- based cancer registry (The Cancer Registry of Vila 
Nova de Gaia). Given the near absence of studies focused only in rectal cancer, our data 
should also be further explored in other future population- based studies.  
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2. Patients and methods 
2.1 Rectal Cancer Registry 
The data were extracted from the Cancer Registry of Vila Nova de Gaia (ROG), founded in 
1981 (Parkin et al., 2002). This registry, near the city of Porto, covers an area of 170 km2, with 
a 2001 census population of 288 749 (139 808 men and 148941 women). The Cancer Registry 
of Vila Nova de Gaia uses active cases from different sources including hospitals, general 
practitioners, the health authority and the district death registration offices. The registry 
collects the cause of death in patient’s death certificate and uses active follow-up to check 
the life status of apparently living patients avoiding the errors relating to incomplete 
ascertainment of death in registered patients with cancer and incomplete ascertainment of 
incident cases. The location of rectal tumours was classified according to the third edition of 
International Classification of Diseases for Oncology (Fritz et al., 1990). For the stage of the 
tumours, we used the 2002 version of the tumour node metastasis (TNM) system, with the 
stage III divided into three prognostic categories (A, B and C) (Greene et al., 2002). For each 
patient, rectal cancer treatment (surgery and/or chemotherapy and/or radiotherapy) was 
individualized according to protocols used at the time of diagnosis.  
2.2 Statistical analysis 
The study concerned the period 1995-2004  (399 cases) using the 1991 and 2001 census in the 
calculation of specific rates by age group, considering the following age groups (years) less 
than 44; 45-54; 55-64; 65-74 and 75 and above and the time periods 1995-1997; 1998-2000 and 
2001-2004. Sex and age- standardized incidence rates were calculated using the European 
population and the ratio of the age- standardized rate between time periods, evaluated by a 
confidence interval of 95%. For both sexes, the tendency of evaluation were analysed by a 
Poisson regression model. χ2 analysis was used to compare categorical variables.  
Overall survival was calculated using the Kaplan- Meier method, and the curves were 
compared through a Log Rank test. The effect of topography and of histological type on 
survival was obtained, by controlling the stage disease, using a Cox proportional hazards 
regression model. Statistical significance was set to P value less than 0, 05. The statistical 
analyses were run in SPSS (version 15, 0; SPSS Inc, Chicago, Illinois, USA). 
3. Results 
There was a slight predominance of males (56.1%) compared with females which corresponds 
of a ratio of 1, 3. Patients’ average age was 67 years old (standard deviation 12.5), with the 
youngest aged 22 years and the older aged 94 years. Rates increased with age over the three 
studied periods mainly in the older women (over age 65 years old) (Figs 1 & 2). 
The crude rates calculated per 100 000 in the three periods analysed are: 17, 7; 18, 5; 16, 6 for 
men, and 9, 9; 12, 2; 15, 1 for women. The age-standardized rates are shown in Table 2. Upon 
analysing the comparison of standardized rate ratio, we conclude that in men the incidence 
had increased from the first period (1995-1997) to the second (1998-2000) in a nonsignificant 
way and decreased significantly during the next period (2001-2004). In women, the 
incidence rates of rectal cancer increased in the three periods, but in a nonsignificant way. 
The cumulative risk of developing rectal cancer before the age of 75 years in Vila Nova de 
Gaia was currently (2001-2005) estimated to be 1, 5 % in men and 1, 1% in women.  
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Age standardized (european) incidence rates 
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Fig. 1. Age- standardized incidence (European population) rates in men over the three 
periods 
 
Age standardized (european) incidence rates 
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Fig. 2. Age- standardized incidence (European population) rates in women over the three 
periods 
www.intechopen.com
 
Rectal Cancer Epidemiology 
 
7 
  Men   
Period ASR SE(ASR) ASR2/ASR1 SRR: 95% CI 
1995-1997 
23,08 2,444 
 
1,21 
 
0,970-1,506 
1998-2000 27,90 2,789   
 
2001-2004 
 
18,26 
 
1,923 
0,67 0,510-0,894 
  Women   
Period ASR SE(ASR) ASR2/ASR1 SRR:95% CI 
1995-1997 
10,59 1,467 
 
1,14 
 
0,879-1,472 
1998-2000 12,04 1,856   
 
2001-2004 
 
13,59 
 
1,680 
1,13 0,950-1,340 
ASR, age standardized rate; CI, confidence interval; SE, standardized error; SIR, standardized incidence 
ratio 
Table 2. Standardized incidence rate ratio and 95% CI: comparison between the three time 
periods (1998-2000 versus 1995-1997 and 2001-2004 versus 1995-1997). 
A Poisson regression model was carried out to check whether the presence of variables such 
as sex, age and period are linked to the risk (Table 3). The incidence of rectal tumours in 
men was higher, and a significant increase in all age groups (45-54; 55-64; 65-74; >75) was 
observed compared with the age group less than 44 years (reference group). Rectal tumours 
showed a nonsignificant increase in 1998-2000 and a nonsignificant decrease during the 
period 2001-2004. In 80% of cases, disease histology comprised adenocarcinomas, and 71, 9% 
of these were located in the rectum. 
 
Variable IRR (95% CI) 
Gender 
Female 
Male 
 
 
Reference category 
1,77 (1,451-2,161) 
Age, years 
<44 
45-54 
55-64 
65-74 
75+ 
 
Reference category 
10,44 (6,172-17,673) 
21,88 (13,356-35,853) 
61,790 (38,679-98,706) 
86,74 (53,845-139,747) 
 
Period 
1995-1997 
1998-2000 
2001-2004 
 
Reference category 
1,16 (0,890-1,520) 
0,98 (0,773-1,256) 
CI, confidence interval; IRR, incidence rate ratio 
Table 3. Results of Poisson regression analysis  
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With regard to the stage, 25,1% of the tumours were diagnosed in stage I , 11,6% in stage II 
(A:8,3%; B:3,3%), 18,6% in stage III (A:3,0%; B:9,3%; C:6,3%), 13% in stage IV and 31,7% were 
unstaged. Upon analysing the stage by periods, we noticed that cases were not detected in 
earlier stages (Table 4). 
 
Period 
 1995-1997 
n (%) 
1998-2000 
n (%) 
2001-2004 
n (%) 
 
Total 
         Stage 
 
I 24 
(24,0) 
34 
(34,0) 
42 
(42,0) 
100 
(100,0) 
II 9 
(19,6) 
8 
(17,4) 
29 
(63,0) 
46 
(100,0) 
III 22 
(29,7) 
22 
(29,7) 
30 
(40,5) 
74 
(100,0) 
IV 10 
(1,9) 
18 
(34,6) 
24 
(46,2) 
52 
(100,0) 
Total 65 
(23,9) 
82 
(30,1) 
125 
(46,0) 
272 
(100,0) 
Table 4. Absolute and relative frequency distribution by stage disease (χ2 =8, 949; d. f. = 6; 
P=0, 18) 
3.1 Survival 
Overall survival, which was 68% at the end of the first year and 50% at the end of 5 years, 
increased over the three periods being analysed (P=0,004; Fig.3).  
 
 
Fig. 3. Overall survival over the three analysed periods 
Figure 4 shows that the difference in survival can be clearly seen for stage IV patients 
(P<0,001). 
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Fig. 4. Overall survival by disease stage 
When analysing survival by subtypes in the 70 stage III patients, significant differences were 
not found (Log Rank test P=0.65). The location of the tumour (junction rectum- colon 
sigmoid versus rectum), after adjustment by stage, is not a significant factor in the prognosis 
for this cancer (Cox proportional hazards analysis: P=0.35). Overall survival is similar in 
adenocarcinomas versus others controlling the stage (Cox proportional hazards analysis: 
P=0.15). 
4. Conclusion  
The results of this study can be summarized as follows: first, there was a general increase in 
the incidence of rectal tumours during the analysed period in both sexes, with a 
predominance of male; second, tumours were considerably more frequent over the age of 45 
years; third, the histological type and the locations analysed have not proven to be 
prognostic factors; finally, we did not observe an increase in early lesions (stage I/II) and 
approximately 20% of the individuals had distant metastatic disease at diagnosis. The 
primary prevention failed. 
High- quality population- based cancer incidence data have been collected throughout the 
World since the early 1960s and published periodically in Cancer Incidence in Five 
Continents (Jemal et al., 2010). However, even in the last publication, the share of World 
population covered is only 11% (Curado et al., 2007). With the data available (Ponz de Leon 
et al., 2000, 2007) and according to our study, rectal cancer is more frequently observed in 
male patients, mainly in older ones (over 65 years). This reflects the expected increases in 
life expectancy and aging of the population (Thun et al., 2010). The differences between 
sexes tend to become smaller over time as it may suggest the slower adoption of certain risk 
behaviours associated with this cancer (Center et al., 2009). For instance, regular uptake of 
smoking worldwide traditionally lags several decades in women compared with men, with 
peak prevalence occurring at a much lower rate (Mackay & Amos, 2003). Additionally, the 
obesity related metabolic pathways that are implicated in rectal cancer are thought to be 
more heavily influenced by visceral abdominal fat that men tend to accumulate more of, 
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compared with women in whom subcutaneous fat is more common (Frezza et al., 2006; 
Pischon et al., 2008). 
In terms of mortality, many authors advocate that the quality of data vary by country, with 
a high accuracy of underlying cause of death noted in longstanding, economically 
developed countries and a lower accuracy reported in newly developed or economically 
transitioning countries (Center et al., 2009). Although the International Classification of the 
Diseases contains a carefully defined set of rules and guidelines that allow underlying cause 
to be selected in a uniform manner, interpretation of the concept probably varies 
considerably (Ferlay et al., 2007). The analysis of any apparent cancer mortality patterns is 
further complicated by the fact that mortality is influenced to a certain degree both by stage 
of the disease at diagnosis and by effectiveness of treatment. Hence the death rate for a 
cancer of equal incidence (i.e. of diagnosed cases) may be different from one country to 
another (Boyle & Smans, 2008). As in other studies, we noticed that rectal cancer survival 
varies, in an inversely way (Jessup et al., 1998; Gunderson et al., 2004) with the stage of the 
cancer (Harling et al., 2004; Rerink et al., 2004). Survival and disease relapse after surgery 
alone (Quirke et al., 1986; Adam et al., 1994) or combined with adjuvant treatment 
(Mohiuddin et al., 2000; Grann et al., 2001; Greene et al., 2001; Kapiteijn et al., 2001; Valentini 
et al., 2001;  Tepper et al., 2002; Mohiuddin et al., 2006; Gunderson & Tepper, 2007) for rectal 
cancer patients are a function of both degree of bowel wall penetration of the primary lesion 
and nodal status. However nodal involvement alone is inadequate as the sole pathologic 
factor to predict survival and relapse rates (Quirke et al., 1986; Adam et al., 1994). Invasion 
through the bowel wall and number of involved lymph nodes are independent high- risk 
factors for both relapse and survival. For patients with a single high- risk factor of either 
direct tumor extension beyond the wall, nodes negative (T3N0), or positive nodes but 
primary tumor confined to the wall (T1-2N1-2), local relapse rates published in older 
surgical series have ranged from 20% to 40% (Gilbert, 1978; Rich et al., 1983). For patients 
with both positive nodes and extension beyond the wall (T3-4N1-2), the risk of pelvic 
relapse was nearly additive (40% to 65% in clinical series and 70% in a reoperative series) 
(Gilbert, 1978; Rich et al., 1983). The rate of systemic metastases is significantly higher for 
patients with both high- risk pathologic factors (extensive beyond rectal wall and positive 
nodes). In the sixth edition of American Joint Committee on Cancer (AJCC) staging (2002) , 
Stage II was subdivided into IIA (T3N0) and IIB (T4NO), and stage III was subdivided into 
IIIA (T1-2N1M0), IIIB (T3-4N1M0), and IIIC (any TN2M0)(14). A recently study, which 
validates the new AJCC staging (7th edition, 2009) for rectal cancer, based in a large cancer 
databases (Gunderson et al., 2009), demonstrates a more favorable prognosis of patients 
with T1-2N1-2 lesions (stage IIIC, AJCC sixth edition) in opposite of a less favorable 
prognosis of patients with T4N1 cancers (stage IIIB, sixth edition). This data supports the 
shift of T1-2N2 lesions from stage IIIC to an earlier stage of the disease (IIIA/IIIB) and T4N1 
lesions from stage IIIB to IIIC and the subdivision of T4, N1 and N2 categories of disease. 
Patients with T4a lesions (penetrates to the surface of visceral peritoneum (revised 
definition, AJCC, seventh edition) have a better prognosis than patients with T4b lesions 
(directly invades or is adherent to other organs or structures) for each N category of disease 
(N0, N1 and N2). Patients with one positive node (N1a) have a better prognosis than 
patients with two to three positive nodes (N1b), and patients with four to five positive 
nodes (N2a) have a better prognosis than patients with seven or more positive nodes (N2b) 
by T category. In summary, the new AJCC seventh edition staging recommended the 
following changes: subdivide IIB into IIB (T4aN0) and IIC (T4bN0); shift more favorable 
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TN2 categories to either IIIA (T1N2a) or IIIB (T2N2a, T1-2N2b, T3N2a); and shift less 
favorable T4N1 lesions from IIIB to IIIC (T4bN1). For a better comprehension, the following 
two tables summarize the alterations of the last three AJCC staging based on TNM 
classifications (Table 5 &6). 
 
Clinical classification 5th edition 
(1997) 
6th edition 
(2002) 
7th edition 
(2009) 
T- primary tumour 
TX     Primary tumour cannot be assessed + + + 
T0     No evidence of primary tumour + + + 
Tis     Carcinoma in situ: intraepithelial or 
invasion of lamina propria 
+ + + 
T1     Tumour invades submucosa + + + 
T2     Tumour invades muscularis propria + + + 
T3     Tumour invades through muscularis 
propria into subserosa or into non-
perinealised pericolic or perirectal 
tissues 
+ + + 
T4     Tumour directly invades into other 
organs or structures and/or perforates 
visceral peritoneum 
+ + + 
T4a    Perforates visceral peritoneum - - + 
T4b    Directly invades other organs or 
structures 
- - + 
N- regional lymph nodes
NX     Regional lymph nodes cannot be 
assessed 
+ + + 
N0     No regional lymph node metastasis + + + 
N1     Metastasis in 1 to 3 regional lymph 
nodes 
+ + + 
N1a    1 node - - + 
N1b    2-3 nodes - - + 
N1c  Satellites in subserosa, without regional 
nodes 
- - + 
N2   Metastasis in 4 or more regional lymph 
nodes 
+ + + 
N2a    4-6 nodes - - + 
N2b    7 or more nodes - - + 
M- distant metastasis
MX     Distant metastasis cannot be assessed + + - 
M0     No distant metastasis + + + 
M1     Distant metastasis + + + 
M1a  Metastasis confined to one organ (liver, 
lung, ovary, non- regional lymph 
node(s)) 
- - + 
M1b    Metastasis in more than one organ on 
the peritoneum 
- - + 
Source: Quirke et al., 2011 
Table 5. Comparative analysis of TNM classification of tumours of the rectum, 5th, 6th and 7th 
edition. 
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Stage Stage grouping 5th edition
(1997) 
6th edition
(2002) 
7th edition 
(2009) 
 T N M    
Stage 0 Tis N0 M0 + + + 
Stage I T1, T2 N0 M0 + + + 
Stage II T3, T4 N0 M0 - - + 
Stage IIA T3 N0 M0 + + + 
Stage IIB T4 N0 M0 + + - 
Stage IIB T4a N0 M0 - - + 
Stage IIC T4b N0 M0 - - + 
Stage III Any T N1, N2 M0 - - + 
Stage IIIA T1, T2 N1 M0 + + + 
Stage IIIA T1, T2 N1c M0 - - + 
Stage IIIA T1 N2a M0 - - + 
Stage IIIB T3, T4 N1 M0 + + - 
Stage IIIB T3, T4a N1/N1c M0 - - + 
Stage IIIB T2, T3 N2a M0 - - + 
Stage IIIB T1, T2 N2b M0 - - + 
Stage IIIC Any T N2 M0 + + - 
Stage IIIC T4a N2a M0 - - + 
Stage IIIC T3, T4a N2b M0 - - + 
Stage IIIC T4b N1, N2 M0 - - + 
Stage IV Any T Any N M1 + + - 
Stage IVA Any T Any N M1a - - + 
Stage IVB Any T Any N M1b - - + 
T tumour, N node, M metastasis 
Source: Quicke et al., 2011  
Table 6. Comparative an analysis of TNM stage grouping of rectal cancer in the last three 
AJCC Staging editions 
Unlike other studies (Ponz de Leon et al., 2004, 2007), during the three analyzed periods, we 
did not observe an increase in early lesions (stage I/II), as there were no statistically 
significant differences in the stages over time. This denotes that primary prevention failed 
even the screening for this cancer has been shown to be effective (Boyle, 1995; Faivre et al., 
2004) and has been cited as one of the most important factors responsible for the recent 
decline in colorectal cancer rates in United States (Espey et al., 2007; Levin et al., 2008). On 
the time of the study, in Portugal, the screening programs were mostly opportunistic which 
is in agreement with the last International Agency for Research Cancer (IARC) publication 
that shows that colorectal cancer screening programs are responsible only for less than 15% 
of the incidence data source worldwide (Curado et al., 2007). Having this dramatic situation 
in mind, the Guidelines Committee of the World Gastroenterology Organization presented 
recently (Winawer et al., 2011), a new conceptual model of cascade colorectal cancer 
screening guidelines that is also evidence based but resource driven. The emphasis in this 
variation of the model is on colonoscopy resources at the top of the cascade for a screening 
goal of prevention by finding and removing the colorectal cancer precursor lesions, the 
adenoma, as well as early detection. The cascade concept says: “do what you can with what 
you have” rather than, “do it this way or no way”. The First Report of Cancer Screening in 
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the European Union (Karsa et al., 2008), demonstrates that colorectal cancer programs are 
currently running or being established in 19 of the 27 Member States. Twelve of the Member 
States have adopted the population- based approach to program implementation 
recommended by the Council of the European Union (Cyprus, Finland, France, Hungary, 
Italy, Poland, Portugal, Romania, Slovenia, Spain, Sweden and the United Kingdom) 
(Klabunde et al., 2001) and seven have established non- population- based programs 
(Austria, Bulgaria, The Czech Republic, Germany, Greece, Latvia and the Slovak Republic). 
With these programs, a total of 70% of population aged 50-74, are covered (Fig. 5).  
 
 
Source: Karsa et al. 2008 
Fig. 5. Proportion of 50-74-year-old women and men targeted for colorectal cancer screening in 
the European Union in 2007, by program type and country implementation status, and women 
and men excluded due to age or lack of regional programs in countries with regional 
implementation status (proportions of 50-74-year-old persons in the EU population in %).  
Variations between the Member States in the way colorectal screening is implemented is 
more pronounced than in other cancer screening like breast cancer. Out of the nineteen 
Member States running or establishing colorectal cancer screening programs in 2007, twelve 
(Bulgaria, Czech Republic, Finland, France, Hungary, Latvia, Portugal, Romania, Slovenia, 
Spain, Sweden, and the United Kingdom) have adopted only the non-invasive test specified 
in the Council Recommendation  (fecal occult blood test- FOBT), six (Austria, Cyprus, 
Germany, Greece, Italy, Slovak Republic) use both the FOBT and an endoscopic test for 
primary screening and one (Poland) uses only an endoscopic test (colonoscopy) (Fig. 6&7). 
With the exception of Italy, in which flexible sigmoidoscopy is the endoscopic screening test 
used in seven loco- regional programs in 2007, the other Member States with endoscopic 
programs have adopted colonoscopy as the primary screening test. Out of 17 Member States 
for which information on the FOBT screening interval is available, 11 have adopted a 2-year 
interval for all participants with a negative test result. The recommended interval for 
colonoscopy is 5 years in Greece and 10 years in the four Member States which have 
adopted endoscopic screening programs. Due to the upper age limits of the respective target 
populations, the number of screening colonoscopies is limited to once or twice in a lifetime 
in Germany and Poland.  
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Source: Karsa et al., 2008 
Fig. 6. Colorectal cancer screening programs based on FOBT (fecal occult blood test) in the 
European Union in 2007, by program type (population-based; non-population-based; no 
program) and country implementation status (population-based: nationwide or regional, 
rollout complete or ongoing, piloting and/or planning; non-population-based: nationwide 
or regional).  
 
 
FS (flexible sigmoidoscopy), CS (colonscopy). 
Source:  Karsa et al., 2008 
Fig. 7. Colorectal cancer screening programs based on novel screening tests still under 
evaluation (Endoscopy) in the European Union in 2007, by program type (population-based; 
non-population-based; no program) and country implementation status (population-based: 
nationwide or regional, rollout complete or ongoing, piloting and/or planning; non-
population-based: nationwide or regional).  
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Despite the variations among countries, we hope that these measures will change in the 
medium term, the current patterns of incidence and mortality of rectal cancer. 
Actually, this cancer remains a major public health problem worldwide. 
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